SOUTH PLAINFIELD, N.J., Oct. 27, 2015 /PRNewswire/ -- (Booth #3) – Leading global genomics service provider, GENEWIZ, will discuss its antibody workflow solutions at the Seventh Annual PEGS Europe Protein & Antibody Engineering Summit, November 2-6 in Lisbon, Portugal. GENEWIZ's Dr. Chris Mozdzierz will also take the podium during the November 3rd luncheon to discuss next generation sequencing of paired VH-VL regions from in vitro selection assays using GENEWIZ's proprietary FuzeSeq™ technology.
"We are excited to have this opportunity to introduce our antibody workflow solutions, including NGS and gene synthesis, to the European protein and antibody scientific research community," said Dr. Lindsay Kendall-Zuill, International Business Marketing Director, GENEWIZ. "Our cutting-edge technologies allow researchers to more quickly advance their antibody discovery process through unique approaches to positive hit screening."
During Dr. Mozdzierz's presentation, he will highlight the benefits of high-throughput, deep sequencing over Sanger sequencing for screening phage display libraries and discovering high affinity antibodies in research, clinical diagnostics, and drug discovery. He will also discuss novel technological approaches that help overcome some of the limitations that still exist, even with traditional next generation sequencing.
For more information about GENEWIZ's antibody workflow solutions, or to schedule a meeting at PEGS Europe, please contact GENEWIZ at +1 908-222-0711, ext. 3 or at firstname.lastname@example.org.
GENEWIZ is a global leader in R&D genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in DNA sequencing, gene synthesis, molecular biology, high-throughput sequencing, bioinformatics, and GLP regulatory-compliant services.
Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a global network of laboratories in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; and Tokyo, Japan. For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, and Weibo.